Market Cap
Novo Nordisk A/S
kr.3.117 Trillion
DKK as of Jan. 1, 2024
US$461.52 Billion
Company | Market Cap (USD) |
---|---|
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Seagen Inc. | $43.15 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
AbbVie | $285.06 B |
Top 1-year algo backtest: +287.69%
$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Novo Nordisk is a global healthcare company involved in the research, development, manufacture, and marketing of pharmaceutical products. It operates through two segments: Diabetes and Obesity care, providing products for insulins, GLP-1, oral antidiabetic products, obesity, and other chronic diseases; and Biopharm, offering products for haemophilia, growth disorders, and hormone replacement therapy.
Novo Nordisk A/S has the following listings and related stock indices.
Stock: OMXC: NOVO.B
Stock: FSX: NOVC
Stock: XETR: NOVC
Stock: XETR: NOVA
Stock: FSX: NOVA
Stock: BMV: NVON
Stock: NYSE: NVO
Stock: Bovespa: N1VO34
The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.